Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: The Company manufactures and distributes apparatus, instruments, and consumables for life science research. Operations are divided into continuing operations (Apparatus and Instrumentation) and discontinued operations (Capital Equipment Business segment, held for sale).
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Revenues (Continuing) | $17.37 million | $16.14 million |
| Gross Profit | $8.88 million | $7.66 million |
| Gross Margin | 51.1% | 47.5% |
| Operating Income | $2.24 million | $1.52 million |
| Net Income (Total) | $0.54 million | $0.20 million |
| Diluted EPS | $0.02 | $0.01 |
| Cash from Operations | $2.37 million | $0.17 million |
| Cash and Equivalents (Total) | $11.90 million | $12.37 million |
| Long-Term Debt (Outstanding) | $8.50 million | $8.50 million |
Note: Net income includes a loss of $1.07 million from discontinued operations. Cash from operations includes both continuing and discontinued activities.
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 7.7% ($1.24 million) year-over-year. Excluding foreign exchange impacts, organic growth was 11.9%, driven by increased demand for pre-clinical testing products.
- Margin Expansion: Gross margin improved to 51.1% from 47.5%, attributed to higher sales volumes, improved product mix, and lower fixed costs.
- Expense Increases: General and administrative expenses rose 14.4% primarily due to the adoption of SFAS 123(R), which recognized $0.4 million in stock-based compensation expense (previously unrecorded under APB 25).
- Cash Flow Improvement: Operating cash flow surged to $2.37 million from $0.17 million, largely due to improved accounts receivable collections ($1.3 million increase) and changes in accrued income taxes.
- Discontinued Operations: The Capital Equipment segment reported a net loss of $1.07 million, compared to $0.68 million in the prior year, reflecting ongoing divestiture activities.
Outlook, Risks, and Management Commentary
- Divestiture Strategy: The Company plans to sell the Capital Equipment Business segment by the end of Q3 2006. Proceeds are intended for debt repayment or further "tuck-under" acquisitions.
- Debt Covenants: The Company has a $20 million revolving credit facility with $8.5 million drawn. The facility expires January 1, 2007. A sale of the Capital Equipment segment requires lender consent; failure to obtain consent could trigger a default and acceleration of debt.
- Capital Needs: Management anticipates needing additional capital for future acquisitions beyond current cash flow and debt capacity, potentially through equity issuance or debt.
- Foreign Exchange: A stronger U.S. dollar negatively impacted reported revenue by approximately $0.7 million. The Company does not currently hedge foreign currency exposure.
- Accounting Changes: Adoption of SFAS 123(R) on Jan 1, 2006, will result in consistently higher reported G&A expenses going forward due to stock-based compensation recognition.
Investor Verification Checklist
- Divestiture Timeline: Verify the status of the Capital Equipment Business sale and whether lender consent has been secured to avoid credit facility default.
- Debt Renewal: Confirm progress on securing a new credit facility before the current one expires on January 1, 2007.
- Stock Compensation Impact: Assess the long-term impact of SFAS 123(R) on future earnings per share and operating margins.
- Foreign Exchange Sensitivity: Monitor currency fluctuations, as international sales (approx. 48% of revenue) are exposed to the Euro and British Pound.
- Discontinued Operations: Review the final valuation and sale terms of the Capital Equipment segment to understand the final impact on the balance sheet.